JP2003150710A - Drug interaction matrix retrieval system - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide a system by which interaction data can simply be retrieved by utilizing a conventional database. SOLUTION: The line numbers L1 and the column numbers C1 of 1 to 10 are displayed at the side of a chart and the top of the chart of the matrix MX of 10×10. At the side of the chart, medical drug name input boxes L2, the number of documents display boxes L3, and warning display boxes L4 are provided corresponding to the line numbers L1 by one to one. On the upper side of the matrix MX, a retrieval execution button B1, a clear button B2, a representative product check button B3, and a non-representative product check button B4 are arranged. When interaction due to the combination use of inputted drugs A and B, e.g. as the result of retrieving an attached document, the matrix MX displays the effect in the square frame of a matrix where A and B cross with each other. In the case of contraindication of combination use, the square frame is displayed in red, and the number of attached documents of A having B written in the box of contraindication of combination use is displayed in brackets is displayed with characters expressing 'contraindication'. In the case of caution of combination use, the square frame is displayed in yellow, and the number of attached documents of A having B written in the box of caution of combination use is displayed in brackets is displayed with characters expressing 'caution'.

Description

Detailed Description of the Invention

[0001]

TECHNICAL FIELD The present invention relates to a drug interaction in which the name of a drug is input to search the package insert database, and the number of package inserts having a description of interaction between concomitant drugs is counted and displayed in a matrix. Matrix search system.

[0002]

There are some medicines that enhance or attenuate the original action when used in combination, and it is necessary to pay sufficient attention to the combination that causes clinical inconvenience. Regarding the interaction of pharmaceuticals, it is becoming more important to deal with it in the future, because it is often used in combination with other drugs and the relationship of side effects has been pointed out.

Reports of drug interactions have been reported in various publications,
Although it is stated in the publications, attached documents, etc., it is expected that such reports will increase more and more in the future, so we will organize these data efficiently and build a database that can be searched using a computer. Is desired. This requires a systematic response and a great deal of expense to collect and keep up-to-date data on drug interaction.

On the other hand, a document attached to a drug (attached document)
Is a public source of information from pharmaceutical companies and is a highly useful source of information regarding drug interactions. Further, this attached document is provided by some service companies as a database that can be used by general users. Therefore, the latest interaction data can be easily searched by using this database.

However, although the items to be included in the package insert have been publicly determined, the method of description varies depending on the pharmaceutical company.
Looking at the interaction section of the package insert, regarding drugs belonging to the same category, for example, sulfonylurea type diabetes drug, sulfonylurea type drug, sulfonylurea type hypoglycemic agent, sulfonylurea type hypoglycemic agent, sulfonylurea type preparation, S
Various expressions such as U agent and sulfonylurea hypoglycemic agent are used, and terms are not unified. In addition, for example, there are many brand names such as Glymicron, Grimylan, and Glutamir that hang from the generic name Gliclazide. Regarding the interaction of drugs, it is not described in the other package, even though the package insert of one of the concomitant drugs has a description of the interaction due to differences in the revision time and the relationship with the new drug. Sometimes.

Therefore, the present invention provides a system for easily searching interaction data using an existing database in consideration of such problems as inconsistency of terms and inconsistency between interaction data. It was made for the purpose.

[0007]

In order to achieve the above object, the present invention has the following constitution.

That is, according to the first aspect of the invention, the package insert database is searched to extract all the package inserts of the n concomitant drug products, and n of any two drugs is combined.
In the case of the combination of × (n-1), the number of package inserts that have a description of interaction with other agents is counted, and this number is placed at the opposite pole position of any two agents sandwiching the diagonal line of the n × n matrix It is a drug interaction matrix retrieval system that displays each. The invention of claim 2 is the drug interaction matrix retrieval system according to claim 1, wherein the number of attached documents displayed in the matrix is used as an index so that the content of the attached document can be referred to. The invention of claim 3 is the drug interaction matrix retrieval system according to claim 1, wherein the term inconsistency in the description of the interaction of the package insert is corrected by a dictionary. The invention according to claim 4 is the drug interaction matrix retrieval system according to claim 1, wherein the number of all package inserts having an interaction description for the n combination drugs is counted and displayed in a matrix. is there.

[0009]

BEST MODE FOR CARRYING OUT THE INVENTION Embodiments of the present invention will be described below with reference to the drawings.

FIG. 1 shows a search screen format of the drug interaction matrix search system embodying the present invention. The search screen displays row numbers L1 and column numbers C1 of 1 to 10 on the front side and the front side of the 10 × 10 matrix MX.
On the front side, a drug name input field L2, a document number display field L3, and a warning display field L4, which correspond one-to-one with the line number L1, are provided. On the top of the table, there is a one-to-one correspondence contraindication display column C with column number C1.
2. A combination caution display column C3 will be provided. Further, a search execution button B1, a clear button B2, a representative item check button B3, and a non-representative item check button B4 are arranged above the matrix MX.

In the drug name input field L2, up to 10 items of generic or merchandise names of drugs to be checked are entered simultaneously. In the example of the figure, a general name or a product name such as "Triamterene" or "Indacine R" is input. Here, the number of medicines to be inputted at the same time is set to 10 items according to the size of the matrix MX, but it may be more or less than 10 items and is not limited to 10 items.

The number-of-documents display column L3 displays the number of relevant attached documents for the input drug name. In the example of the figure, it is shown that there are four product name attachment documents of the common name “Triamterene”. When the number of documents is clicked, a list of four attached documents is displayed, and when one of them is clicked, the content of the attached document is displayed.

The warning display field L4 displays the number of attached documents with warnings for the entered drug name. In the example of the figure, out of the five attached documents of "tacrolimus", all five attached documents have a description of "warning". If you click the warning number, 5
A list of attached documents is displayed, and when one of the attached documents is clicked, the content of the attached document is displayed.

The contraindication concomitant display column C2 reversely displays the number of other package inserts with contraindications for the entered drug name. In the example of the figure, it is shown that there are 34 attached documents for which "triamterene" in line number [1] is described as a contraindication. When the number of contraindications for combined use is clicked, a list of 34 attached documents is displayed, and when one of them is clicked, the content of the attached document is displayed.

The combination notice display column C3 reversely displays the number of other attached documents with the description of combination notice for the inputted drug name. The example in the figure shows that there are 1349 attached documents for which "triam terene" in line number [1] is described with a caution for combined use. Clicking the combination caution number will display a list of 1349 attached documents, and clicking one of them will display the contents of the attached document.

The matrix MX displays the fact in the square frame of the matrix where A and B cross when there is an interaction due to the combined use between the inputted medicines A and B as a result of searching the package insert. In the case of contraindications for concomitant use, the square frame is displayed in red, and the number of the package inserts of A that have B in the contraindication column for concomitant use are displayed in parentheses with the letters "prohibition". In the example in the figure, out of the four attached documents for "Triamterene" in line number [1], "Indacine R" and "Voltaren SR" in line numbers [2] and [3] are listed in the contraindication column for that document. It indicates that there are four attached documents. In addition, the number of attached documents of “Indacin R” on line number [2] is 1
It shows that, out of the number of cases, there is one attached document in which "Triamterene" of line number [1] is written in the contraindication column. Clicking the forbidden number displays a list of 4 or 1 attached documents, and further clicking one of them displays the contents of the attached document.

This is because the product with the generic name "Triamterene" is contraindicated with "Indomethacin" which is the generic name of "Indacine R", and "Voltaren S".
Since there is a contraindication for combined use with "Diclofenac" which is a general name of "R", it is displayed as such. Both the generic name and the product name are entered in the drug name input field L2, so
A general name dictionary and a product name dictionary are included so that the common name and product name match. In addition, a drug efficacy dictionary is inserted to replace the drug efficacy classification name with a generic name for searching.

In the case of caution for combined use, a rectangular frame is displayed in yellow, and together with the letters "Note", it is displayed in parentheses how many attached documents of A having B in the caution column for combined use are present. In the example in the figure, while there are 25 attached documents for "ibuprofen" in line number [4], there are 23 attached documents for which "tacrolimus" in line number [5] is described in the combination caution column. Shows. "Ibuprofen" and "Tacrolimus" both have a combination caution statement, but of the 25 "ibuprofen" package inserts, 2 are ointments and ointments are not cautions, so 23 are displayed. The combination notice displays the number of only the attached documents with such a description. Also, the number of attached documents for "Tacrolimus" in line number [5] is 5
It shows that, out of the cases, there are four attached documents in which "Ibuprofen" in line number [4] is mentioned in the combination caution column. Clicking on the note number will display a list of 23 or 4 attached documents, and clicking on one of them will display the contents of the attached document.

In the example shown in the figure, "forbidden" and "note" are placed in the rectangular frame of the matrix in which "triamterene" at row number [1] and "indasin R" and "voltaren SR" at column numbers [2] and [3] cross. Both characters are displayed. This is displayed because "Indacine R" and "Voltaren SR", which were first described in the combination caution column of the package insert of "Triamterene", were changed and changed in the contraindications column next.

In addition, "triamterene" on line number [1]
And "Voltaren SR" of column number [3] crosses, there is a "forbidden" sign in the square frame of the matrix, but "Voltaren SR" of row number [3] and "Triamterene" of column number [1] The square frame of the crossing matrix is "Note"
Is displayed. This is because the indication of "prohibition" of "Triamteren" is correct, and only the attached document of "Voltaren SR" is confirmed, and the judgment is wrong.

[Triamterene] at line number [1]
And "Ibuprofen" in column number [4] cross, there is a "Note" in the square frame of the matrix, but "Ibuprofen" in row number [4] and "Triamterene" in column number [1] cross There is no display in the square frame of the matrix. Similarly, there is no display in the square frame of the matrix where "Triamterene" at line number [1] and "Tacrolimus" at column number [5] cross, but "Tacrolimus" at column number [5] and column number [1] In the square frame of the matrix that "Triamterene" crosses, there is a "prohibition" sign. In this way, the package insert does not mean that both sides have the same description,
It is necessary to confirm both package inserts used together.

This is a problem caused by the revision time of the package insert, and one package is revised later than the other. In the case of new drugs, the interaction with existing drugs is known, so it is stated in the package insert,
In the case of conventional drugs, the description of the interaction is often delayed because the new drug is unknown.

FIG. 2 shows a search processing flow of the drug interaction matrix search system embodying the present invention. The search process is a drug name search process 1 in which the drug name index file F6 is searched to obtain the drug name document number bit string (A).
01 and the combination contraindication index file F7 to obtain the combination contraindication document number bit string (B)
02 and the combination caution index file F8 to retrieve the combination caution document number bit string (C)
03 and a drug name document number bit string (A) and a contraindicated concomitant document number bit string (B) to generate a contraindicated contraindication bit string (D), and a contraindicated contraindication determination process 104 for determining contraindications between drug names. , The medicine name document number bit string (A) and the combination caution document number bit string (C) are multiplied to generate a combination caution determination bit string (E), and the combination caution determination processing 105 determines the combination caution between drug names. .

The drug name search processing 101 searches the drug name index file F6 using the generic name or the product name entered in the drug name input field L2 as a key, and extracts all the attached document numbers for each drug name. , Obtain the drug name document number bit string (A) in which they are arranged in a bit string having the same length as the number of documents. This drug name document number bit string (A)
The number of bits = 1 is counted to display the number of relevant documents and the number of warning cautious administration documents in the document number display column L3 and the warning display column L4, respectively.

In the contraindication search process 102, the contraindication index file F7 is searched by using the generic name or the product name entered in the drug name input field L2 as a key to search for all package inserts subject to contraindication for each drug name. Extract the numbers and arrange them into a bit string with the same length as the number of documents to obtain the contraindicated document number bit string (B). Counting the number of bits = 1 in this contraindication document number bit string (B), contraindication display column C2
Display the number of other documents that have a contraindication for concomitant use.

The combination caution search process 103 searches the combination caution index file F8 by using the generic name or the product name entered in the drug name input field L2 as a key, and searches for all attached documents subject to combination caution for each drug name. Extract the numbers and arrange them into a bit string of the same length as the number of documents to obtain the combination caution document number bit string (C). This combination caution document number bit string (C) bit = 1 is counted and the combination caution display column C3
Display the number of other documents for which there is a note of combined use.

The contraindication for concomitant use determination 104 determines the contraindication for concomitant use of drug names by obtaining the logical product (AND) of the drug name document number bit string (A) and the contraindication document number bit string (B) acquired for each drug name. Use contraindication bit string (D)
To generate. By counting the number of bits = 1 in this contraindication bit string (D), the number of documents of other drug names with contraindications is displayed in the square frame of the matrix where the drug names of interest cross each other.

The combination caution determination process 105 determines the combination caution between drug names by obtaining the logical product (AND) of the drug name document number bit string (A) and the combination caution document number bit string (C) acquired for each drug name. Use combination judgment bit string (E)
To generate. The number of bits = 1 in this combination caution determination bit string (E) is counted, and the number of documents of other drug names with a caution statement is displayed in the square frame of the matrix where the target drug names cross each other.

FIG. 3 shows a data creation processing flow of the drug interaction matrix retrieval system embodying the present invention. The data creation process is performed by inputting the package insert data D1 and extracting the drug name extraction file F1, the contraindication extraction file F2,
Extraction process 201 for outputting the combination caution extraction file F3
And contraindication extraction file F2, combination caution extraction file F
Type 3 to enter the drug efficacy dictionary T1, generic name dictionary T2, product name dictionary
With reference to T3, the expansion processing 202 that outputs the contraindication expansion file F4 and the combination caution expansion file F5, the drug name extraction file F1, the combination contraindication expansion file F4, and the combination caution expansion file F5 are input and the drug name index file F6 , A combination contraindication index file F7 and a combination caution index file F8.

In the extraction processing 201, commercially available package insert data D1 described in SGML document is input to extract <generic name>, <product name>, <generic name>, and the drug name extraction file with the document number. Output to F1. Also, <interaction>
<Contraindication for combined use> and <Caution for combined use> BODY part is extracted, and it is output to the combined use contraindicated extraction file F2 and the combined use caution extraction file F3 together with the document number.

The expansion processing 202 is a combined contraindication extraction file
Use the caution extraction file F3 together with F2 to enter the drug efficacy dictionary T
1. Refer to the generic name dictionary T2 and the product name dictionary T3, and expand the drug name described in the drug name category into the generic name and the drug name described in the generic name into the product name together with the document number. Output to the contraindication development file F4 and the combination caution development file F5, respectively.

In the indexing process 203, the drug name extraction file F1 is input, sorted by drug name, and the drug name and the document number are associated with each other and output to the drug name index file F6. Also, enter the contraindications development file F4 and the attention cautions development file F5, sort by drug name in the same way, and use the contraindication index file F7 by associating drug names with document numbers.
Outputs to caution file F8.

The drug interaction matrix search system embodying the present invention is configured as described above, and the drug name is entered in the drug name input field L2 on the search screen to execute the search execution button B1.
When the button is clicked, the search process is started and the search results are displayed in the document number display column L3, the warning display column L4, the combined contraindication display column C2, the combined caution display column C3, and the matrix MX, respectively.

When the drug name is input to the clear button B2 and the user clicks the drug name, the input drug name is erased and the drug name input field L2 returns to the original empty state. If the representative item check button B3 is clicked before executing the search, the attached document is searched for only the representative item. When an attached document is searched by inputting a general name, many attached documents will be hit if there is a generic product (generic product), but the search target can be narrowed down to representative items. When the non-representative item check button B4 is clicked before executing the search, the attached document is searched for the non-representative item. As a result, the search target can be narrowed down to pharmaceutical products excluding representative products. If neither the typical item nor the non-typical item is specified, the search is executed for all attached documents. The representative products here are those with an early release date, those that are used at the same level as or higher than the original product even if it is a generic product, if the generic product has a standard only for that pharmaceutical company, or if it is a pharmacopoeia, it is attached The standards are set based on those of pharmaceutical companies that are expected to respond quickly to document revisions.

[0035]

As described above, the drug interaction matrix search system of the present invention extracts all package inserts of n concomitant drugs and combines two arbitrary drugs among them n × (n-1). In this combination, the number of package inserts having a description of interaction with other agents is counted, and the number is displayed at the opposite polar positions of any two agents sandwiching the diagonal line of the n × n matrix. Therefore, according to the present invention, even if there is no description of the interaction in one package insert of the concomitant drug, if there is a description in the other package, the number of cases is displayed on the other side. It is possible to supplement deficiencies such as.

Further, the drug interaction matrix retrieval system of the present invention can refer to the contents of the attached document by indexing the number of attached documents displayed in the matrix. Therefore, according to the present invention, the contents of the attached document in which the interaction is described can be examined in more detail in the series of search processing.

Further, the drug interaction matrix retrieval system of the present invention corrects the inconsistency of terms in the description of the interaction in the package insert with the dictionary. Therefore, according to the present invention, as a result, the hit rate of the search is increased, and the existing database can be used as it is without changing the content of the dictionary only by changing the contents of the dictionary according to the matching status of the terms.

Further, the drug interaction matrix retrieval system of the present invention counts the number of all package inserts that have a description of interaction for a concomitant drug and displays them in a matrix. Therefore, according to the present invention, all the interactions including other attached documents in which the interactions are described can be examined from various directions in a series of search processes.

[Brief description of drawings]

FIG. 1 is a search screen format of a drug interaction matrix search system embodying the present invention.

FIG. 2 is a search processing flow of the drug interaction matrix search system embodying the present invention.

FIG. 3 is a data creation processing flow of the drug interaction matrix retrieval system embodying the present invention.

[Explanation of symbols]

101 Drug name search processing 102 Contraindication search processing 103 Combination caution search processing 104 Contraindication for contraindication 105 Combination caution determination process 101 Drug name search processing 201 Extraction process 202 Expansion processing 203 Indexing process A drug name document number bit string B contraindicated document number bit string C combination caution document number bit string D contraindicated contraindication bit string E Combination caution bit string B1 Search execution button B2 Clear button B3 representative item check button B4 Check button other than representative items C1 column number C2 contraindication display column C3 combined use caution display column D1 Attachment data F1 drug name extraction file F2 combined contraindication extraction file F3 combination caution extraction file F4 contraindication development file F5 combination caution expansion file F6 Drug name index file F7 contraindication index file F8 combination caution index file L1 line number L2 drug name input field L3 document number display column L4 warning display column MX Matrix T1 drug efficacy dictionary T2 common name dictionary T3 product name dictionary

Claims (4)

[Claims] 1. A package insert database is searched to extract all corresponding package inserts of n concomitant drug products, and in the combination of n × (n-1) in which any two drugs are combined, A drug interaction matrix retrieval system in which the number of package inserts with interactions described between them is counted, and the number is displayed at the opposite polar positions of any two drugs sandwiching the diagonal line of the n × n matrix. 2. The drug interaction matrix retrieval system according to claim 1, wherein the contents of the attached document can be referred to by indexing the number of attached documents displayed in the matrix. 3. The drug interaction matrix retrieval system according to claim 1, wherein inconsistency of terms in the description of the interaction of the package insert is corrected with a dictionary. 4. The drug interaction matrix retrieval system according to claim 1, wherein the number of all package inserts having an interaction description for the n combination drugs is counted and displayed in a matrix.